# Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

> **NCT03066206** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 93 (actual)

## Conditions studied

- EGFR Exon 20 Mutation
- ERBB2 Gene Mutation
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **DRUG:** Poziotinib

## Key facts

- **NCT ID:** NCT03066206
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-17
- **Primary completion:** 2026-02-16
- **Final completion:** 2026-02-16
- **Target enrollment:** 93 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066206, "Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03066206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*